Acute kidney injury and nephrotic syndrome associated with eltrombopag therapy in chronic idiopathic thrombocytopenic purpura
- 7 April 2021
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 14 (4) , e241462
Abstract
A 77-year-old man was admitted with severe acute kidney injury and nephrotic syndrome. He was started on eltrombopag for chronic idiopathic thrombocytopenic purpura 6 weeks earlier. An ultrasound of the kidneys was normal and an auto-antibody screen was negative. The use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between the patient’s development of acute renal failure and eltrombopag therapy. Literature review identified only one other case of nephrotic syndrome and acute kidney injury associated with eltrombopag therapy in which a kidney biopsy revealed focal segmental glomerulosclerosis. Due to the challenges faced during the prevailing SARS-CoV-2 pandemic and persistent low platelet counts a renal biopsy was not undertaken. On stopping eltrombopag, the patients renal function stabilised and he successfully went into remission following treatment with high dose corticosteroids and diuretics. This report of a serious case of reversible renal failure and nephrotic syndrome after treatment with eltrombopag may serve to inform clinicians about the possible severe renal adverse effects of eltrombopag before its commencement for future use.Keywords
This publication has 10 references indexed in Scilit:
- The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human UseHaematologica, 2011
- Focal Segmental Glomerulosclerosis with Acute Renal Failure Associated with Eltrombopag TherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
- Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopagAmerican Journal of Hematology, 2010
- Effects of TGF-β on Podocyte Growth and Disease Progression in Proliferative PodocytopathiesKidney and Blood Pressure Research, 2010
- Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor AgonistStem Cells, 2009
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 2007
- Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis CNew England Journal of Medicine, 2007
- Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistBlood, 2007
- The role of transforming growth factor‐β in PEG‐rHuMGDF‐induced reversible myelofibrosis in ratsBritish Journal of Haematology, 1997
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981